Bisphenol A Test · Urine

BPA (bisphenol A) sits inside food can linings, thermal paper receipts, polycarbonate plastics, and many of the products you touch every day. Biomonitoring studies find it in the urine of nearly everyone tested, and in 2023 European regulators reduced their estimate of a tolerable daily intake by roughly 20,000-fold after reviewing the latest health evidence. By that newer benchmark, 100% of women in 14 of 15 European studies exceeded the health-based guidance level.

This test captures how much of that exposure is moving through your body, measured in a urine sample. It does not diagnose a disease. It gives you a window into your personal contact with a chemical that human studies have repeatedly linked to metabolic, hormonal, and cardiovascular problems, and it lets you see whether changes you make actually move the needle.

What This Test Actually Measures

After exposure, BPA is rapidly processed by the liver and gut and most of it leaves the body in urine within hours. Urinary BPA is the standard biomarker of recent exposure. Results are typically reported as micrograms per gram of creatinine, which is a way of correcting for how concentrated or dilute your urine sample is.

Because BPA leaves the body quickly, this is not a measurement of long-term storage. It is a snapshot of what reached your system in the hours and days before the sample. That makes the trend over time more useful than any single number.

Heart Disease and Mortality

The largest signal comes from US population data. In a study of 9,243 adults followed in the National Health and Nutrition Examination Survey from 2003 to 2016, higher urinary BPA was associated with higher cardiovascular death risk, with the link more pronounced in women than men. A separate analysis of 3,883 adults from the same survey found higher BPA exposure was significantly associated with all-cause mortality.

A meta-analysis combining the survey data with other studies reported a dose-dependent rise in cardiovascular disease risk as BPA exposure climbed. Another cross-sectional analysis of 9,139 US adults found urinary BPA was positively correlated with stroke, heart failure, and angina, with stronger associations in men. The pattern in some studies was J-shaped, where risk was highest at the upper end of exposure.

Type 2 Diabetes and Metabolic Health

Higher BPA tracks consistently with obesity, insulin resistance, and metabolic syndrome. A meta-analysis of epidemiological studies found that each 1 nanogram per milliliter increase in BPA exposure was associated with about an 11% higher risk of obesity, regardless of obesity type, sex, or age. A separate review reported that BPA exposure was significantly associated with abdominal obesity.

In a clinical study of 60 people with type 2 diabetes, those with higher serum BPA (a related but blood-based measurement, not the urine test) had poorer glycemic control, more insulin resistance, signs of accelerated cellular aging, and shorter telomeres. Mechanistic work in adipose tissue suggests BPA drives inflammation through a signaling molecule called IL-17A, which can worsen insulin resistance.

Liver and Fatty Liver Disease

Reviews of human and mechanistic data link higher BPA exposure to non-alcoholic fatty liver disease, also called NAFLD or by its newer name MASLD (metabolic dysfunction-associated steatotic liver disease). The proposed pathway involves BPA disrupting how the liver handles fats, promoting insulin resistance, and triggering low-grade inflammation in the liver.

Reproductive and Hormonal Effects

BPA acts as a weak imitator of estrogen and an interferer with androgen signaling. In women, higher exposure has been associated with diminished ovarian reserve, fewer antral follicles, lower AMH (anti-Mullerian hormone, an ovarian reserve marker), recurrent miscarriage, gestational diabetes, lower birth weight, and preterm delivery. Most studies of polycystic ovary syndrome find higher BPA in affected women, alongside higher androgens, more insulin resistance, and chronic inflammation.

If you are trying to conceive, are pregnant, or are working through a fertility evaluation, BPA exposure is one of the few modifiable environmental factors with consistent human evidence behind it.

Cancer Risk

In a Spanish arm of the European Prospective Investigation into Cancer and Nutrition study (4,812 participants), serum BPA above the detection limit was associated with higher prostate cancer risk, though no link was seen with breast cancer in that cohort. A separate study of 52 women undergoing breast surgery found higher BPA in both urine and breast adipose tissue of breast cancer patients than in controls. In 96 overweight or obese patients with thyroid nodules, higher BPA exposure was associated with greater malignancy risk and higher TSH (thyroid-stimulating hormone, the main signal of thyroid function).

Reference Ranges and What Counts as High

BPA is a research and exposure marker, not a marker with established clinical decision thresholds like cholesterol or blood sugar. There is no consensus cutoff that separates safe from dangerous urinary BPA. The European Food Safety Authority's tolerable daily intake estimates an exposure dose, not a urine concentration, and applying it back to urine values is approximate at best.

Population studies typically describe results by where you fall in the distribution rather than by a fixed threshold. The values below come from large biomonitoring datasets and are illustrative orientation, not a clinical target. Different labs and different methods will produce different numbers.

Compare your results within the same lab over time for the most meaningful trend. Different assays produce different numbers for the same person.

Why One Reading Is Not Enough

BPA varies more from sample to sample than almost any biomarker you can measure. Within-person reproducibility studies tracking the same women across one to three years found an intraclass correlation coefficient of about 0.14, where 1.0 would mean perfect consistency. Studies measuring multiple samples across a single week found similarly low values, around 0.1 to 0.2.

What that means in practice: a single urine BPA value is a noisy snapshot. Modeling suggests you would need around 5 spot samples spread across days and times of day to get even fair reproducibility. Treat one number as a prompt to retest, not as a verdict.

A reasonable cadence: get a baseline test now, repeat in 3 to 6 months if you are actively reducing your exposure, and at least once a year afterward. If you are pregnant, trying to conceive, or making aggressive changes, retesting every 3 months gives you faster feedback.

When Results Can Be Misleading

• Time of day: levels follow a daily rhythm, generally higher in morning and evening and lower in mid-afternoon, tracking meal patterns. Sampling at different times of day on different visits will produce different numbers even if your true exposure is steady.
• Recent food and drink: a meal from a can, plastic-wrapped item, or polycarbonate water bottle can push your level up for hours. If you want a representative reading, avoid those sources for at least 24 hours before sampling.
• Recent receipt handling: thermal paper receipts can transfer BPA through skin. Cashiers, retail workers, and frequent receipt handlers often have higher levels reflecting genuine occupational exposure rather than measurement error.
• Hydration: very dilute or very concentrated urine can shift the raw number. Reporting in micrograms per gram of creatinine partially corrects for this, but extreme dehydration or overhydration can still distort results.

What an Elevated Result Should Make You Do

A high BPA reading is not a diagnosis, but it does justify an exposure audit and a closer look at related health markers. The decision pathway depends on your context.

• Identify your top exposure source. Diet (especially canned foods and packaged items) and thermal paper handling are the two largest contributors in most adults. Walk through a typical day and find your biggest sources.
• Pair with metabolic and hormonal markers. If your BPA is consistently elevated, look at fasting glucose, HbA1c, insulin, lipid panel, and liver enzymes (ALT, AST). For women evaluating fertility, add AMH, FSH, LH, and estradiol.
• Retest after changes. Since BPA clears within hours, a meaningful shift in habits should show up in a follow-up test within weeks to months.
• Consider testing related substitutes. Many BPA-free products use bisphenol S (BPS) or bisphenol F (BPF), which human and laboratory data suggest can have similar or stronger hormonal activity. A BPA-only test may underestimate your total exposure to this class of chemicals.

The BPA-Free Trap

When manufacturers removed BPA, many switched to bisphenol S and bisphenol F. A systematic review comparing BPS and BPF to BPA concluded they are as hormonally active as BPA, with similar endocrine-disrupting effects. Newer reviews of BPA analogues find they are now widely detected in human urine, sometimes at levels rivaling BPA itself. A BPA test alone tells you about one molecule. If you are working hard to reduce exposure, testing the substitutes alongside BPA gives a more honest picture.